Liver Progenitor Cell Formulation for Microenvironment Remodeling

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods are inadequate in promoting liver regeneration and improving liver function to prevent the progression of chronic liver diseases such as cirrhosis, as they fail to effectively regulate the liver regeneration microenvironment.

Innovation Solution

A liver disease regulatory formulation comprising hepatocyte-derived liver progenitor cells or their secretory supernatant, which includes specific miRNAs like miRNA-182, miRNA-183, and miRNA-574, and active ingredients that inhibit hepatic stellate cell activation or induce their death, promoting liver cell proliferation and immune tolerance.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional methods are used to treat liver disease, then treatment is provided, but they fail to effectively promote liver regeneration and improve liver function

Engineering Contradiction:

Improveliver regeneration effectivenessVSAvoidliver function improvement rate

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent uses hepatocyte-derived liver progenitor cells as intermediary elements that mediate between the existing liver tissue and the regenerative process. These progenitor cells act as a bridge to restore liver function by differentiating into functional hepatocytes and modulating the liver microenvironment, thereby resolving the contradiction between reliable regeneration and improved liver function productivity.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes key parameters of the liver microenvironment including immune cell composition, cytokine levels, and extracellular matrix properties. By adjusting these parameters through progenitor cell therapy, the system transforms the regenerative capacity of the liver, enabling both reliable regeneration and improved functional output simultaneously.

Inventive Principle:

Principle #35Parameter changes

2Stability of the object's composition

If the liver regeneration microenvironment is not regulated, then natural progression occurs, but chronic liver diseases progress to cirrhosis

Engineering Contradiction:

Improveliver microenvironment stabilityVSAvoidchronic liver disease progression

Core Design Contradiction:

Stability of the object's compositionVSObject-affected harmful factors

Solution Approach 1:

The patent implements feedback mechanisms where liver progenitor cells sense the liver microenvironment status and respond by modulating immune cell activity, cytokine secretion, and tissue remodeling. This feedback loop stabilizes the microenvironment by counteracting pathological changes before they progress to cirrhosis, resolving the contradiction between maintaining stability and preventing disease progression.

Inventive Principle:

Principle #23Feedback

Solution Approach 2:

The patent applies preliminary anti-action by using progenitor cells to preemptively counteract the harmful effects of chronic liver disease. The progenitor cells are introduced before cirrhosis develops to prevent fibrosis progression and maintain microenvironment stability, thereby stopping disease progression at an earlier stage.

Inventive Principle:

Principle #9Preliminary anti-action

3Reliability

If hepatic stellate cells are activated, then fibrosis response is triggered, but liver function deteriorates

Engineering Contradiction:

Improvefibrosis response activationVSAvoidliver damage from stellate cell activation

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful activation of hepatic stellate cells into a beneficial process by using liver progenitor cells to modulate their activity. The progenitor cells transform the fibrotic response from a harmful process into a controlled regenerative process where stellate cells contribute to tissue repair without causing excessive fibrosis or liver damage.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS20230414676A1Liver disease regulatory formulation and use thereof

Publication Date: 2023.12.28 SHANGHAI CELLIVER BIOTECHNOLOGY CO LTD

AI summary

An objective of the present invention is to provide a liver disease regulatory formulation, which is beneficial to prevent the occurrence and development of a chronic liver disease by remodeling a liver regeneration microenvironment. The liver disease regulatory formulation, comprises a hepatocyte-derived liver progenitor cell or a secretory supernatant of the hepatocyte-derived liver progenitor cell.